Epilepsy is one of the most common neurological conditions among older adults—new-onset seizures actually peak after age 65, often triggered by stroke, dementia, brain injury, or tumors. For Medicare beneficiaries living with epilepsy or a seizure disorder, the costs span daily medications, regular brain and electrical monitoring, and in some cases implanted devices or surgery. This guide explains how Medicare covers each piece, where the affordable capped drugs sit versus the uncapped procedures, and how to protect yourself from the largest out-of-pocket risks.

Anti-Seizure Drugs: Part D and the $2,000 Cap

The foundation of epilepsy treatment is a daily anti-seizure medication (ASM), usually taken for life. These are self-administered pills covered under Part D, and most are inexpensive generics:

  • Common generics—levetiracetam (Keppra), lamotrigine (Lamictal), valproate, carbamazepine, phenytoin, topiramate, oxcarbazepine, and gabapentin—are typically low-tier, low-copay drugs.
  • Brand-name and newer agents—brivaracetam (Briviact), lacosamide (Vimpat), perampanel (Fycompa), cenobamate (Xcopri), and cannabidiol (Epidiolex)—carry much higher list prices.

The key protection: under the 2025 Part D redesign, your total annual out-of-pocket for all covered Part D drugs is capped at $2,000, with the option to spread payments through the Medicare Prescription Payment Plan. For someone whose seizures are only controlled on a brand-name agent like Xcopri or Vimpat, that cap turns a potentially crushing bill into a predictable one. Most beneficiaries on standard generics pay well under the cap.

Because roughly a third of epilepsy patients have drug-resistant epilepsy requiring two or more agents—often including expensive newer drugs—this cap is genuinely meaningful for the epilepsy population. This is the favorable, capped side of the Part B vs. Part D drug split; the uncapped exposure appears with monitoring, devices, and surgery below.

Diagnosis and Monitoring Under Part B

Diagnosing epilepsy and adjusting treatment requires testing that runs through Part B at 80 percent after the $257 deductible (2026), leaving 20 percent coinsurance:

  • EEG (electroencephalogram)—the core test of the brain’s electrical activity, from a routine outpatient EEG to ambulatory home EEG.
  • Video-EEG monitoring—prolonged monitoring to characterize seizures, often performed in an epilepsy monitoring unit (EMU). When admitted as an inpatient, this falls under Part A and its benefit-period deductible; when outpatient, under Part B.
  • Brain imaging—MRI and CT to find structural causes such as a stroke, tumor, or scarring—covered under Part B at 20 percent coinsurance.
  • Neurologist and epileptologist visits, plus blood tests to check drug levels—lab tests processed by a clinical laboratory are covered at zero coinsurance.

For older adults, this workup is especially important because new seizures often signal an underlying problem like a prior stroke that itself needs management.

Implanted Devices: VNS and RNS

When medications don’t control seizures, Medicare covers neurostimulation devices for eligible patients:

  • Vagus nerve stimulation (VNS)—a device implanted under the skin of the chest that stimulates the vagus nerve to reduce seizure frequency.
  • Responsive neurostimulation (RNS)—a device implanted in the skull that detects and responds to seizure activity.
  • Deep brain stimulation (DBS)—approved for certain drug-resistant epilepsy.

The implant surgery is typically a Part A inpatient or Part B outpatient procedure depending on the setting, and the device, programming, and battery replacements carry 20 percent Part B coinsurance with no annual cap. These are high-dollar items—the surgery and device can run into the tens of thousands—so the uncapped coinsurance exposure here is substantial without supplemental coverage.

Epilepsy Surgery

For some patients with seizures arising from a single, identifiable area of the brain, resective surgery (removing the seizure focus) or laser ablation can dramatically reduce or eliminate seizures. These procedures are covered when medically necessary, generally as Part A inpatient care subject to the $1,676 benefit-period deductible (2026), with the surgeon’s services billed under Part B. A pre-surgical evaluation—often including inpatient video-EEG and specialized imaging—precedes any operation.

Emergency Seizures and Status Epilepticus

A prolonged seizure or cluster—status epilepticus—is a medical emergency. Medicare covers the full chain of acute care:

  • Ambulance transport to the hospital is covered under Part B when other transportation would endanger your health.
  • Emergency department care and any inpatient hospitalization to stabilize seizures fall under Part A (inpatient) or Part B (outpatient/observation), subject to the usual deductibles. The observation-versus-inpatient distinction matters here just as it does for other conditions, because it affects your cost-sharing and any later skilled-nursing eligibility.
  • Rescue medications—such as nasal midazolam (Nayzilam) or diazepam (Valtoco) that families use to stop a cluster at home—are Part D drugs under the $2,000 cap.

Beneficiaries with frequent seizures should make sure both their rescue medication and a clear seizure action plan are in place, since emergency care is the most expensive and disruptive way to manage breakthrough seizures.

A Concrete Cost Example

Consider two beneficiaries with epilepsy on Original Medicare without a supplement:

  • Dorothy has well-controlled seizures on generic levetiracetam. Her drug copays are a few dollars a month, and aside from an annual neurology visit and occasional labs, her costs are minimal—comfortably a few hundred dollars a year.
  • Frank has drug-resistant epilepsy. After trying several agents, he needs brand-name Xcopri (held in check by the $2,000 Part D cap), undergoes inpatient video-EEG monitoring, and ultimately receives a VNS device. His uncapped 20 percent Part B/Part A coinsurance on the monitoring admission, the implant surgery, and the device could reach well into the thousands. For Frank, a Medigap Plan G would have converted that unpredictable exposure into just the annual deductible.

The contrast shows why the same diagnosis can cost a few hundred dollars or several thousand depending on disease severity and supplemental coverage.

Driving, Safety, and What Medicare Doesn’t Cover

Medicare covers the medical care of epilepsy, but not everything beneficiaries need:

  • Custodial supervision—help for someone who can’t be left alone due to frequent seizures isn’t covered when that supervision is the only care needed. This long-term care gap may require long-term care insurance or Medicaid planning.
  • Home safety modifications and medical alert systems are generally not covered.
  • Mental health support—depression and anxiety are common with epilepsy and are covered under Medicare’s mental health benefits.

If epilepsy is severe enough to prevent work in someone under 65, Social Security disability may provide a path to Medicare itself—see our disability benefits guide.

Why Supplemental Coverage Matters

Epilepsy splits cleanly into a capped, affordable drug side (Part D, $2,000 ceiling) and an uncapped procedure side (Part B/Part A monitoring, devices, and surgery). For well-controlled patients on generics, costs are modest. For drug-resistant patients heading toward video-EEG, a VNS/RNS device, or surgery, the uncapped 20 percent Part B coinsurance becomes the dominant risk.

  • Medigap Plan G pays that 20 percent with no annual limit, so EEG monitoring, the device implant, and follow-up programming leave you owing essentially only the small Part B deductible.
  • Medicare Advantage caps annual in-network out-of-pocket but adds prior authorization and network limits—worth weighing if you need a specific epilepsy center or epileptologist. Compare the approaches in our Medicare Advantage vs. Original Medicare guide and the cost-focused breakdown.

Help With Costs

  • Extra Help (Low-Income Subsidy) sharply lowers Part D drug costs—valuable for patients on expensive newer anti-seizure agents.
  • Medicare Savings Programs can pay your Part B premium and, at the QMB level, your Part B coinsurance—relieving the uncapped monitoring and device exposure.
  • The Epilepsy Foundation offers care navigation, drug-assistance referrals, and support resources.

The Bottom Line

Medicare covers epilepsy comprehensively: anti-seizure drugs under Part D’s $2,000 cap, EEG and MRI monitoring under Part B, and VNS, RNS, and surgery for drug-resistant cases. Daily treatment for most beneficiaries sits on the capped, affordable side of Medicare’s drug split. The financial risk concentrates in the uncapped 20 percent coinsurance on monitoring, implanted devices, and surgery—precisely what Medigap Plan G is designed to eliminate. Pairing Medicare with a good supplement (where affordable) and tapping Extra Help and Medicare Savings Programs is what keeps a lifelong seizure disorder financially manageable. For the wider picture, see our guide to healthcare costs in retirement.